Capricor Therapeutics Inc
CAPRStock
$19.12+183.43%52W
Market Cap$1.14B
P/E—
Div yield—
Beta0.35
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-32.11%
Price vs S&P 500 (4W)-22.48%
VGM Score37.86
Market Capitalization$1.14B
Earnings Surprise History
Q1 26-0.59est. -0.54
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.19
4.13
4.13
4.19
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CAPRCapricor Therapeutics Inc | F | C | C | $19.12 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases with high unmet medical needs. Its lead candidate, deramiocel (an allogeneic cardiac-derived cell therapy), is in Phase 3 clinical development for Duchenne muscular dystrophy. The company's proprietary StealthX platform supports preclinical research in vaccine delivery and targeted molecular therapeutics.